Imcivree (Setmelanotide)

Setmelanotide is a selective agonist of the melanocortin‑4 receptor (MC4R). By activating MC4R in the hypothalamus, it restores normal signaling in the melanocortin pathway, which suppresses hunger signals and enhances energy expenditure, leading to weight loss in patients with relevant genetic defects.

The dosing regimen for Imcivree is individualized. A qualified prescriber determines the appropriate dose and titration schedule based on the patient’s specific genetic condition, clinical response, and safety considerations. Patients should follow the prescribing information provided by their healthcare professional.

The safety of Imcivree in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a specialist obstetrician.

To order Imcivree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Imcivree is distinct because it targets the melanocortin‑4 receptor pathway and is approved only for rare genetic forms of obesity. Most other anti‑obesity agents act on appetite centres via different mechanisms, such as GLP‑1 receptor agonists, and are indicated for broader populations.

Imcivree must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. Proper cold‑chain handling is essential to maintain product stability.

Imcivree is supplied as an injectable solution for subcutaneous injection. The injection is typically given in the abdomen, thigh or upper arm by a trained healthcare professional, following the dosing schedule prescribed by the treating physician.

Serious risks include severe hypersensitivity reactions (anaphylaxis), suicidal ideation or behaviour, and extensive hyperpigmentation. Patients should be monitored closely for any signs of allergic reaction, changes in mood, or unexpected skin changes, and seek immediate medical attention if they occur.

Imcivree is contraindicated in individuals with known hypersensitivity to setmelanotide or any excipients in the formulation. It should also be avoided in patients without the approved genetic indications, as the benefit‑risk profile has not been established for other forms of obesity.